"Safe in the Wound"
NAMSA GLP Independent Laboratory Animal Study
(Full Study is Available)
“The in-life assessment for each animal was clinically normal upon entering the study and all animals remained healthy during the in-life portion of the study. There were two minor health observations (post-operative swelling & inappetence) and no adverse events noted during the study. According to the physical examinations, the clinical pathology results, the daily observations, the procedures, and the in-life assessment all animals in this study demonstrated adequate health to assess the objective of the study.”
To paraphrase the summary, other than surgical swelling at a couple of the sites and temporary loss of appetite after the surgery, all animals observed after the 4-week period were in the same condition as they were when they started. The StopsBleeding™/BleedStop™ powder in the animals' bodies had no adverse effect on any of the three animals or in any of the 12 sites.
“Mild post-operative inflammation was noted in all 3 animals, which is normal post-operative sequella. These conditions were treated with additional analgesic medications (ibuprofen & meloxicam SR) and jackets to protect the integrity of the implant sites. Mild inappetence was noted briefly in all animals, which is to be expected after a procedure. All the animals in this study were otherwise healthy throughout the in-life portion of the study.”
StopsBleeding™ and BleedStop™ are trade names of CoAg Medical LLC for their hemostatic powder and rigid foam products. Both products, StopsBleeding™ and BleedStop™, are identical except for the name. It is marketed under two different names due to the high cost of marketing to hospitals and the medical community, who end up paying more than the consumer.